MBDB is Uncontrolled in the United States. That said, it may be an analog of a scheduled substance.
Addictive Potential: Unknown
Emergency Room Visits Yearly: Unknown
Mandatory Minimum Sentence: Unknown
Mechanism of Action: Increases Serotonin and Dopamine
Overview:
Methylbenzodioxolylbutanamine (MBDB; Methyl-J; Eden) is a psychedelic, stimulant, and empathogen-entactogen of the phenethylamine chemical class. MBDB is a closely related chemical analogue of methylenedioxymethamphetamine (MDMA), with the only difference between the two molecules being an ethyl group instead of a methyl group attached to the alpha carbon.
MBDB was tested by Alexander Shulgin and described in his book, PiHKAL (Phenethylamines i Have Known And Loved). MBDB's dosage, according to PiHKAL, is 180–210 mg; the proper dosage relative to body mass seems unknown. Its duration is 4–6 hours, with noticeable after-effects lasting for 1–3 hours.
MBDB was initially developed as a non-psychedelic entactogen. It has lower effects on the dopamine system in comparison to other entactogens such as MDMA. MBDB causes many mild, MDMA-like effects, such as lowering of social barriers and inhibitions, pronounced sense of empathy and compassion, mood lift, and mild euphoria are all present. However, MBDB's effects are much less profound than those of MDMA. MBDB tends to produce less euphoria, psychedelia, and stimulation in comparison. Many users declare that MBDB is a "watered-down" version of MDMA. Despite these features which make MBDB less desirable as a recreational drug, it has been suggested that the drug may have greater therapeutic potential than MDMA.
bk-MBDB, also known as butylone and β-keto-N-methylbenzodioxolylpropylamine is the β-keto analogue of MBDB. It shares the same relationship to MBDB as Methylone does to MDMA.
Pharmacology:
The major acute neuropharmacological effects of MBDB in the rat are an increase in serotonin release in the brain and the inhibition of serotonin and noradrenaline reuptake. These effects compare well with those of MDMA, although the latter is more potent as a re-uptake inhibitor and releaser. MBDB may also slightly increase dopamine release and inhibit dopamine re-uptake, but with a far weaker potency than MDMA. This is important, as dopamine release has been implicated in the serotonin neurotoxicity caused by MDMA and in the reinforcing qualities of substances such as cocaine and amphetamine (EMC, 1998).
Side Effects and Adverse Reactions:
MBDB is a research chemical. Research chemicals are experimental chemicals that are not approved for human consumption. This is because not enough data exists currently about their side effects, adverse reactions, long term damage, addiction potential, etc. Although some people are willing to ingest research chemicals, it is not reasonable to assume that they are in any way safe to use recreationally.
The NeuroSoup Trip Guide - The free e-book version of The Neurosoup Trip Guide is now available online. It contains chapters on Choosing the Right Hallucinogen; Set, Setting, and Preparation for a Trip; Tips for Tripsitters; Aspects of the Entheogenic Experience; Working with Difficult Experiences; Integration; and References and Recommended Reading.
